| Literature DB >> 33480204 |
Federica Cozza1,2, Andrea Lizio1, Lucia Catherine Greco1, Stefania Bona1, Giordana Donvito1, Elena Carraro1, Silvia Tavazzi3, Nicola Ticozzi4,5, Barbara Poletti4, Valeria Ada Sansone1,6, Christian Lunetta1.
Abstract
BACKGROUND ANDEntities:
Keywords: Edinburgh Cognitive and Behavioural ALS Screen; Milano-Torino staging; amyotrophic lateral sclerosis; ocular motility; optometric analysis; visual system
Year: 2021 PMID: 33480204 PMCID: PMC7840315 DOI: 10.3988/jcn.2021.17.1.96
Source DB: PubMed Journal: J Clin Neurol ISSN: 1738-6586 Impact factor: 3.077
Description of the study cohort
| Demographic and clinical characteristics | Values |
|---|---|
| Age at evaluation, years | 63.99 [55.26–70.71] |
| Disease duration, months | 42.90 [21.93–82.73] |
| Diagnostic delay, months | 12.17 [7.07–21.37] |
| Disease progression rate, ALSFRS-r score unit/months | 0.50 [0.26–0.89] |
| Sex, male | 118 (59) |
| C9ORF72 expansion | 5 (3) |
| Site of onset, bulbar | 38 (19) |
| EEC, definite | 34 (17) |
| NIV at evaluation | 92 (46) |
| IV at evaluation | 9 (5) |
| PEG at evaluation | 31 (16) |
| Ocular device used | |
| ETCD user | 23 (12) |
| Functional features | |
| MiToS | |
| 0 | 50 (34) |
| 1 | 34 (23) |
| 2 | 32 (21) |
| 3 | 15 (10) |
| 4 | 18 (12) |
| Missing | 51 |
| ALSFRS-r | |
| Total score | 29 [18–36] |
| Bulbar-subscale score | 10 [6–12] |
| Spinal-subscale score | 11 [4–15] |
| Respiratory-subscale score | 10 [3–12] |
| Cognitive assessment | |
| ECAS total score | 105.00 [92.00–115.00] |
Data are n (%) or median [interquartile range] values.
ALSFRS-r: Amyotrophic Lateral Sclerosis Functional Rating Scale–revised, ECAS: Edinburgh Cognitive and Behavioural ALS Screen, EEC: El-Escorial Criteria, ETCD: eye-tracking communication device, IV: invasive ventilation, MiToS: Milano-Torino staging, NIV: noninvasive ventilation, PEG: percutaneous endoscopic gastrostomy.
Fig. 1Distribution of ocular symptoms. *Symptomatic patients include both mildly and severely symptomatic groups.
Results of optometric tests
| Optometric tests | Values |
|---|---|
| NSUCO oculomotor test | |
| Saccades accuracy | |
| Unacceptable values, 1–3 | 90 (46) |
| Acceptable values, 4 or 5 | 105 (54) |
| Pursuit accuracy | |
| Unacceptable values, 1–3 | 121 (61) |
| Acceptable values, 4 or 5 | 76 (39) |
| Saccade head movements | |
| Unacceptable values, 1–3 | 79 (42) |
| Acceptable values, 4 or 5 | 107 (58) |
| Pursuit head movements | |
| Unacceptable values, 1–3 | 69 (37) |
| Acceptable values, 4 or 5 | 119 (63) |
| Broad-H test | |
| Abnormal eye movements | 29 (15) |
| NPC | |
| Unacceptable values, break point ≥15 cm | 57 (29) |
| Acceptable values, break point <15 cm | 142 (71) |
| Cover test | |
| Far heterotropia | 12 (6) |
| Near heterotropia | 16 (8) |
| Refractive condition | |
| Right-eye spherical equivalent, diopters | 0.25 [-1.00 to 1.25] |
| Left-eye spherical equivalent, diopters | 0.12 [-0.75 to 1.12] |
| Best-corrected visual acuity, logMAR | 0.00 [0.00 to 0.00] |
Data are n (%) or median [interquartile range] values.
logMAR: logarithm of the minimum angle of resolution, NPC: near point of convergence, NSUCO: Northeastern State University College of Optometry.
Significant associations between optometric findings and ETCD use
| Optometric findings | Number of ETCD user, | ||
|---|---|---|---|
| Univariate analysis | Multivariable analysis* | ||
| Symptoms | <0.0001 | 0.0006 | |
| Asymptomatic | 3 (5) | ||
| Mildly symptomatic | 1 (2) | ||
| Severely symptomatic | 19 (26) | ||
| Blurred vision | 0.0035 | 0.0029 | |
| No | 8 (6) | ||
| Yes | 15 (20) | ||
| Burning eye sensation | <0.0001 | 0.0005 | |
| No | 4 (3) | ||
| Yes | 19 (26) | ||
| Eye strain | <0.0001 | <0.0001 | |
| No | 6 (4) | ||
| Yes | 17 (33) | ||
| Watering eyes | <0.0001 | 0.0005 | |
| No | |||
| Yes | 12 (27) | ||
| Photophobia | <0.0001 | 0.0021 | |
| No | 1 (6) | ||
| Yes | 13 (32) | ||
Data are n (%) values.
*p value adjusted for sex, disease progression rate, disease duration, and diagnostic delay.
ETCD: eye-tracking communication device.
Significant associations between ocular symptoms and functional and staging status
| Functional features | Scores by symptoms | Univariate analysis | Multivariable analysis† | ||
|---|---|---|---|---|---|
| Severely symptomatic patients | |||||
| ALSFRS-r bulbar-subscale | 11 [7–12] | 10 [8–11] | 8 [3–10] | 0.0003 | 0.0016 |
| ALSFRS-r spinal-subscale | 12 [8–17] | 12 [8–16] | 7 [0–12] | 0.0001 | 0.0004 |
| ALSFRS-r respiratory-subscale | 11 [5–12] | 11 [3–12] | 6 [2–11] | 0.0007 | 0.0006 |
| ALSFRS-r total | 33 [24–38] | 31 [22–37] | 19 [9–31] | <0.0001 | <0.0001 |
| MiToS>* | 16 (33%) | 12 (27%) | 37 (66%) | 0.0054 | 0.0008 |
| ALSFRS-r bulbar-subscale | 10 [7–12] | 9 [3–11] | 0.0124 | 0.0143 | |
| ALSFRS-r total | 31 [22–36] | 26 [12–36] | 0.0351 | 0.0075 | |
| Eye strain | |||||
| ALSFRS-r bulbar-subscale | 10 [7–12] | 8 [2–10] | 0.0002 | 0.0002 | |
| ALSFRS-r spinal-subscale | 12 [7–16] | 8 [0–11] | <0.0001 | 0.0003 | |
| ALSFRS-r respiratory-subscale | 11 [5–12] | 5 [2–10] | <0.0001 | 0.0002 | |
| ALSFRS-r total score | 31 [23–38] | 18 [9–27] | <0.0001 | <0.0001 | |
| MiToS>1* | 36 (33%) | 29 (67%) | 0.0002 | 0.0002 | |
| ALSFRS-r bulbar-subscale | 11 [8–12] | 8 [2–10] | <0.0001 | 0.0002 | |
| ALSFRS-r spinal-subscale | 12 [9–17] | 6 [0–12] | <0.0001 | <0.0001 | |
| ALSFRS-r respiratory-subscale | 11 [5–12] | 6 [2–11] | 0.0012 | 0.0027 | |
| ALSFRS-r total | 32 [24–38] | 19 [9–31] | <0.0001 | <0.0001 | |
| MiToS>1* | 29 (31%) | 36 (63%) | 0.0002 | <0.0001 | |
| ALSFRS-r spinal-subscale | 12 [8–16] | 9 [0–15] | 0.0038 | 0.0125 | |
| ALSFRS-r respiratory-subscale | 11 [3–16] | 6 [1–11] | 0.0021 | 0.0045 | |
| ALSFRS-r total | 31 [22–38] | 22 [8–32] | 0.0015 | 0.0036 | |
| MiToS>1* | 35 (33%) | 21 (64%) | 0.0020 | 0.0032 | |
| ALSFRS-r bulbar-subscale | 10 [7–12] | 6 [2–9] | <0.0001 | 0.0003 | |
| ALSFRS-r spinal-subscale | 12 [7–15] | 4 [0–12] | 0.0026 | 0.0405 | |
| ALSFRS-r respiratory-subscale | 10 [4–12] | 4 [1–10] | 0.0043 | 0.0037 | |
| ALSFRS-r total | 30 [22–37] | 17 [4–29] | 0.0001 | 0.0008 | |
| MiToS>1* | 45 (37%) | 20 (69%) | 0.0022 | 0.0056 | |
Data are n (%) or median [interquartile range] values.
*Comparison between patients who lost up to one function and patients who lost multiple functions, †p value adjusted for sex, disease progression rate, disease duration, and diagnostic delay.
ALSFRS-r: Amyotrophic Lateral Sclerosis Functional Rating Scale–revised, MiToS: Milano-Torino staging.
Significant associations between optometric findings and functional status
| Functional features | Scores by optometric findings | Univariate analysis | Multivariable analysis* | |
|---|---|---|---|---|
| Abnormal saccade head movements | Normal saccade head movements | p | p | |
| ALSFRS-r bulbar-subscale | 9 [5–11] | 10 [8–12] | 0.0026 | ns |
| ALSFRS-r bulbar-subscale | 9 [6–11] | 10 [8–12] | 0.0256 | ns |
| ALSFRS-r bulbar-subscale | 7 [2–11] | 10 [7–12] | 0.0292 | ns |
| ALSFRS-r bulbar-subscale | 8 [3–10] | 10 [7–12] | 0.0003 | 0.0040 |
| ALSFRS-r total | 25 [8–33] | 30 [21–37] | 0.0123 | 0.0389 |
Data are median [interquartile range] values.
*p value adjusted for sex, disease progression rate, disease duration, and diagnostic delay.
ALSFRS-r: Amyotrophic Lateral Sclerosis Functional Rating Scale–revised, NPC: near point of convergence, ns: not significant.
Significant associations between optometric findings and cognitive status
| Cognitive assessment | Scores by optometric findings | Univariate analysis | Multivariable analysis* | |
|---|---|---|---|---|
| Abnormal saccade accuracy | Normal saccade accuracy | p | p | |
| ECAS total | 95.0 [84.0–108.0] | 111.0 [103.0–117.0] | <0.0001 | 0.001 |
| ECAS total | 96.0 [85.0–105.0] | 111.0 [102.0–116.0] | 0.0006 | 0.0105 |
| ECAS total | 98.0 [85.0–111.0] | 111.0 [103.5–116.5] | 0.0027 | 0.0290 |
| ECAS total | 96.0 [84.0–108.0] | 111.0 [102.0–116.0] | 0.0019 | 0.0202 |
| ECAS total | 84.0 [69.0–99.0] | 108.0 [96.0–115.0] | 0.0246 | 0.0210 |
Data are median [interquartile range] values.
*p value adjusted for sex, disease progression rate, disease duration, and diagnostic delay.
ECAS: Edinburgh Cognitive and Behavioural ALS Screen.